Research work · 1999
Strontium and Bone
Walter Eduardo Cabrera, Iris Schrooten, Marc E. De Broe, Patrick C. D’Haese
Journal of Bone and Mineral Research
Abstract
Strontium (Sr; MW 87.62) is ranked fifteenth in the order of the elemental crustal abundance in which it occurs at a concentration of 450 mg/kg.1 The element was first isolated in an impure form in 1808 and named after "Strontian," a Scottish town where it was found at high concentrations in calcareous rocks consisting of natural apatites in which strontium may occur at concentrations as high as 73 g/kg.2 In ocean water, strontium is the most abundant trace element, reaching values of up to 8 mg/l. Natural water sources, such as rivers, springs, and wells, contain smaller amounts of the element ranging from 0.021 mg/l up to 0.375 mg/l.3, 4 Strontium is a natural constituent of food and beverages. Meat, poultry, vegetables, and fruit contain relatively low amounts of the element (range 0.3–5.1 mg/kg), whereas in cereals, grains, and seafood it may be present at concentrations of up to 25 mg/kg. Hence, the strontium content of the human diet and the daily intake of the element varies according to the geographic area and the type of food consumed.4-6 A limited number of the series of radioactive strontium isotopes have been applied to the fields of medicine, biology, and biochemistry. The therapeutic potential of intravenously administered strontium-89 was first recognized in 1940 with the discovery that it could be used for the treatment of bone pain from metastatic prostate cancer.7 The latter isotope, as well as strontium-85 and strontium-88 have been primarily used as markers of calcium metabolism. Research on the toxicity of strontium has so far been focused mainly on the biological effects of radioactive strontium-90, which is an important constituent of nuclear fallout.8 At that time dietary supplementation of stable strontium was reported to inhibit the intestinal absorption of strontium-90, thereby serving as a deterrent to ingestion of radioactive strontium. However, caution was warranted with these preventive measures since replacement of dietary calcium with strontium was found to result in diminished growth, improper bone mineralization, and an inhibition of intestinal calcium absorption.9, 10 The gastrointestinal tract represents the main route of entry of strontium into the body. The gastrointestinal absorption of strontium largely depends on age and may vary from 90% of the element's dietary intake in infants to only 10% in the elderly.11 Within a given age group, important interindividual fluctuations of the gastrointestinal absorption have also been observed, which have been ascribed to the actual functional state of the gastrointestinal tract.12 Several mechanisms for strontium transport through the intestinal wall have been postulated. Some authors suggested that in contrast to calcium, strontium is absorbed entirely via passive diffusion, i.e., paracellular transport.13, 14 However, Papworth et al. proposed two routes of entry for the element: carrier-mediated and diffusion-mediated.15 With the exception of infants, it can generally be stated that strontium is absorbed to a lower extent than calcium, the strontium/calcium absorption ratio being ∼0.50.16 The intestinal absorption of strontium increases under fasting conditions and is negatively affected by a high dietary content of calcium, phosphate, or chelating agents, such as sodium alginates,17, 18 which are of substantial interest in view of their ability to inhibit the intestinal absorption of the element in animals and man without affecting calcium absorption.19, 20 Experimental studies have further demonstrated that intestinal strontium absorption is gradually increased during pregnancy and lactation, with a maximal fractional absorption at the end of the lactation period.21 In addition to the gastrointestinal pathway, absorption of the element may also take place via the lung and skin.5 Studies on the kinetics of strontium have mainly been performed in connection with those of calcium. Indeed, in previous experiments it has been suggested that the two elements not only share some chemical and physical characteristics but also exhibit similar involvements in a number of biological processes.5 Hence, the term observed ratio (OR) introduced by Comar et al.22 (for example: ORbone-diet = [strontium/calcium of bone]/[strontium/calcium of diet]) has been used by several authors to describe a number of aspects of the strontium metabolism, e.g., express the discrimination of strontium absorption, accumulation, and tissue deposition in relation to calcium.17, 23, 24 In animals kept on a normal calcium and strontium diet, 98.6% of the calcium and 99.1% of the absorbed strontium are deposited in bone, respectively. Under normal conditions, the bone strontium/calcium ratio varies between 1:1000 and 1:2000, which is on the same order as that noted in serum.25 Little is known about the extracellular, cellular, and subcellular localization of strontium in bone, which must be ascribed to the lack of accurate and sensitive staining and analytical methods able to demonstrate the element at a given ultrastructural site in bone. In one study, Boivin et al.,26 by means of X-ray fluorescence (XRF) analysis, demonstrated strontium to be localized in mineralized bone. At this site, the element appeared to be distributed rather heterogeneously, the highest concentration being present in newly formed bone. Recently, by means of electron probe X-ray microanalysis (EPXMA) of bone of renal failure rats loaded with strontium, Schrooten et al. found the element to be present in calcified bone in close proximity to the mineralization front.27 Blood is the second most important bodily location of strontium. Data in the literature on normal serum strontium levels in subjects with intact renal function vary between 10 μg/l and 217 μg/l and greatly depend on the analytical technique used.5 In uremic patients, either treated or not by hemodialysis, data in general point toward increased serum strontium levels as compared with subjects with normal renal function.28, 29 Recent preliminary findings of our group indicate that serum strontium levels in dialysis patients may differ greatly from center to center, ranging from values comparable to those noted in subjects with normal renal function (14 ± 7 μg/l) up to 30-fold higher, i.e., mean ± SD of 29 ± 11 μg/l, in the center with the lowest strontium concentrations, as compared with 466 ± 90 μg/l in the center with the highest levels. Although evidence still has to be presented, this wide concentration range most likely is due to differences in the dialysate strontium concentration and perhaps variations in the dietary intake. The oral intake of aluminum-containing phosphate binders, particularly Maalox® tablets, which may contain up to 217 μg/g of the element, has also been suggested as an important source of strontium within the dialysis population.30 To what extent renal insufficiency by itself also leads to increased strontium levels is the subject of current investigations. No clear-cut data on the protein binding of strontium in serum are available. Reported values on the protein-bound fraction of the element vary between 20% and 40% and depend on the technique used.31, 32 Strontium is excreted in urine and to a lesser extent in feces and sweat. In healthy adults, the total clearance varies between 9.4 ml/minute and 11.7 ml/minute, while the renal clearance appears to vary between 4.0 ml/minute and 5.4 ml/minute.33 Strontium excreted in feces either originates from nonabsorbed, orally administered strontium or strontium that is actively excreted by the intestine, which was found to correlate positively with the concentration of the element in blood.34 Once absorbed, strontium is distributed throughout the body but preferentially deposited in bone and teeth.35 Evidence has been presented in the literature that strontium may exert a number of effects on bone which may be either beneficial36-41 or toxic.42-46 As mainly demonstrated in rats with normal renal function, the element may, depending on the dose administered, interact either directly or indirectly (Table 1). Data in the literature indicate that a high dietary intake of strontium (strontium content in food or drinking water >4 g/l) may disturb bone mineralization.9, 38, 41 The mechanism by which strontium exerts a deleterious effect on bone calcification is not yet known. Several potential mechanisms have been put forward. From a chemical point of view, one may reasonably accept that because of the larger size of the strontium ion as compared with that of calcium, hydroxyapatite crystals will preferentially bind calcium as compared with strontium. At high strontium concentrations, however, the element may replace calcium in bone by heteroionic exchange.44 This takes place via a pure physicochemical process independent of the osteoblast and will ultimately result in a decreased bone calcium content.45 In addition, incorporation of the greater sized strontium ions in bone will induce a mild distortion of the crystal lattice,46 impair crystal growth, and increase the dissolution of mineralized bone.47 As a consequence, lower bone mineral density (BMD) is likely to be expected in strontium overload. Changes in the bone mineral chemistry, such as the carbonate content,39 have been reported also but require further experimental evidence. In rats with intact renal function, the development of rickets, a bone disease characterized by defective bone mineralization, was induced after adding the element to the animals' drinking water at a 4 g/l concentration. Here the observed bone lesions were more pronounced in young rats as compared with the adult animals.38, 39 In the search for a role of strontium in the development of a mineralization defect, the ability of the element to enter cells via the calcium channels and its subsequent incorporation at intracellular calcium binding sites, such as the endoplasmatic reticulum, thereby affecting the intracellular calcium homeostasis and calcium-mediated processes involved in bone mineralization, should be taken into account.48, 49 Here the element's hypothetical ability to disturb the calcium-regulated bicarbonate secretion of the osteoblast buffering the proton release during hydroxyapatite formation50 is worth considering as a possible underlying mechanism for the impaired mineralization. Chemical interactions that occur at high strontium doses will result in hypomineralization reflected by lower BMD. In this context, the opposite effects strontium and fluor exhibit on bone in terms of BMD is worth mentioning. In contrast to strontium, fluor appears to influence bone mineralization by shifting the mineralization profile toward hypermineralization. Unlike strontium, fluor does not substitute for calcium in the apatite lattice, and deposition of the latter element in bone has been reported to increase crystallinity.39 Biochemically it was demonstrated that rats fed a high strontium diet had a significantly greater amount of bone glycosaminoglycans, i.e., noncollageneous proteins, as compared with control animals.45 Interestingly, several of these noncollageneous bone proteins, such as osteopontin and bone sialoprotein, may alter bone mineralization, as indicated by their ability to prevent hydroxyapatite precipitation when added to supersaturated calcium phosphate solutions.51 While strontium seems to have an effect on the noncollageneous proteins, such as the proteoglycans, it appears not to interfere with the bone collagen content.39 Defective mineralization has also been associated with a comparatively high matrix vesicle volume fraction in the lower part of the growth plate, which may reflect a reduced rate of matrix vesicle degradation,52 a process that repeatedly has been assigned a central role in the mineralization process.53 In in vitro as well as in vivo studies, Neufeld and Boskey54 found that the strontium-induced mineralization defect was accompanied by an accumulation of the complexed acid–phospholipid content. These complexes have been found in all apatite-containing mineralizing tissues studied to date and appear to play a role in initiating mineralization in vivo.55 Others suggested that strontium interferes with bone mineralization by its ability to bind to the calcifiable collageneous matrix at potential Ca2+-binding sites.56 Histologic and radiographical studies on the effect of strontium in the rat show that the longitudinal growth of tibiae and endochondral ossification are apparently inhibited by strontium administration. The zone of the hypertrophic cartilage plate became wider, delaying the endochondreal ossification.41 In experimental studies using rats with normal renal function, histologic examination of bone samples revealed the oral administration of low strontium doses (Sr content in diet <4/gl) to increase both the bone formation rate and trabecular bone density. This observation was found to be due to a strontium-induced stimulation of the osteoblastic activity evidenced by an increase in the amount of osteoid, which was noted in the absence of any mineralization defect or any change in osteoclastic surface or in the number of active bone-resorbing cells.38, 39 The fact that the increased osteoblastic activity was not accompanied by increased bone resorption was suggested to be due to covering of the endosteal bone surface with osteoid, by which bone resorption was prevented.57 Others found that the ability of strontium to act as an uncoupling agent of both processes might be responsible for this observation.40 The effects of strontium on bone metabolism might be of particular interest when put into a pathological as well as a therapeutical perspective. Indeed, the observed increase in the trabecular bone volume as noted in the rat in the presence of low strontium doses may have therapeutic applications, particularly in pathologic conditions characterized by an accelerated bone remodeling process and extensive demineralization.25 This may also explain the therapeutic response to relatively low oral strontium doses in patients with metastatic cancer. Here a distinct remineralization of the bone lesions was reflected by a definite improvement of the erosion margin of vertebral metastases, indicating that a stimulated osteogenesis was noted.25, 46 These beneficial effects of strontium are somewhat in contrast with the failure of calcium supplements to recalcify osteopenic areas in some particular metabolic bone diseases. Most likely this is due to a strict homeostatic control of the plasma calcium level, which does not permit a transfer of the element to decalcified regions, in contrast to strontium, for which a preferential transfer to areas presenting active bone remodeling has been reported.25 A beneficial effect of low strontium doses has also been noted in osteoporotic patients. Here an increase in the vertebral bone calcification was reported. It is not clear, however, whether this effect resulted from either a decreased bone resorption and/or increased bone formation.36 We were the first to demonstrate that intermediate doses of strontium (3 g/l as SrCl2·6H2O in the drinking water) can induce osteomalacia in chronic renal failure rats, as evidenced by increased osteoid in combination with reduced bone mineralization.27 This appears to be in contrast with the positive effects of low doses of strontium administered to rats with normal renal function. In this context, the similarities of strontium with fluor in the development of a mineralization defect are worth mentioning. Whereas administration of fluor to rats with normal renal function exerts a rapid stimulatory effect on the bone matrix synthesis,58 Ittel et al., in a chronic renal failure rat model, recently found that fluoride added to the drinking water (40 mg/l) results in an exacerbation of the osteomalacic lesion induced by aluminum.59 These findings are more or less in line with another experimental study where in rats with chronic renal failure high doses of fluoride (50 mg/kg) caused osteomalacia, as evidenced by an increase in osteoid parameters and diminished bone strength.60 Recently, Schrooten et al. in a chronic renal failure rat model27 studied the effects of both strontium and aluminum on bone. Whereas daily dietary loading of strontium (3 g/l in the drinking water) resulted in the development of osteomalacia, those receiving aluminum at a daily oral dose of Al (10 mg Al(OH)3/10 g of rat chow + 10 mg/l as AlCl3 to the drinking water) developed adynamic bone disease. This pathology, characterized by a decreased mineralization in the absence of an increased osteoid, suggests an effect of aluminum on osteoblast activity rather than on mineralization.27 These findings are in line with studies performed in rats with normal renal function, where aluminum administration led to a decrease in bone and matrix formation, which was not accompanied by an increase in osteoid.61, 62 It should be mentioned, however, that others in both experimental and in vitro studies have reported opposite results, i.e., found aluminum to stimulate bone formation.63, 64 To what extent these discrepancies are either due to differences in the animal or in vitro models, interactions with systemic or local factors, differences in speciation, variations in dose, or means of administration of the various aluminum compounds is not yet clearly understood.65 Another interesting finding in the above-mentioned study27 is concerned with the observation that rats that were simultaneously loaded with strontium and aluminum either developed adynamic bone disease or (severe) osteomalacia. This observation and the notion that in rats loaded with aluminum only adynamic bone was seen, suggests that the so-called "aluminum-induced osteomalacia" in dialysis patients might not be solely due to aluminum, but could be the result of a multielement effect. A potential interaction of aluminum with other toxins or metabolic modulating abnormalities, in the development of both osteomalacia and/or adynamic bone disease, was postulated more than a decade ago by Quarles et al.66, 67 With respect to their ambiguous effects on bone, the parallel between aluminum and strontium is at least remarkable. When given at low doses, aluminum has been shown to stimulate the de novo bone formation. As assessed in beagles with normal renal function, this appears to result from stimulation of mesenchymal precursors forming a primitive type of bone distinct from coupled bone formation.68 Data obtained with the MC3T3-E1 osteoblast cell line suggest that the aluminum-induced neo-osteogenesis and DNA stimulation may take place through an extracellular cation-sensing mechanism coupled with G-protein activation and signaling cascades involving diacylglycerol and protein kinase C pathways.69 This is an interesting hypothesis deserving further study. The physicochemical similarities between strontium and calcium and, hence, the potential agonistic effects of strontium with such a calcium-sensing mechanism in both osteoblasts and osteoclasts might also explain why under certain experimental conditions strontium and other divalent and trivalent cations (e.g., Al3+) increase trabecular bone volume and prevent bone loss.39, 40, 70, 71 In other words, it might be the pathway by which particular cationic substances uncouple bone formation and bone resorption, leading to a net increase in bone mass.72 Further studies establishing the molecular identity of the putative cation receptor(s) in bone cells, confirming cell-specific expression, and determining their functional role in bone remodeling will be of particular interest to get a better insight into the mechanism underlying the often ambiguous effects of strontium and aluminum on bone. Aside from its direct effects on bone, strontium also seems to affect bone metabolism indirectly. As for the direct effects, these indirect interferences with bone metabolism also seem to take place in a dose-dependent way (Table 1). As outlined above, rats fed a high strontium diet may develop hypocalcemia.9, 42, 43 A strontium-induced bone mineralization defect, however, has also been observed in rats receiving a low calcium diet39 as well as in those where the calcium content was normal41 or enriched.73 et found that the bone lesions after of strontium from the Interestingly, of the bone lesions was accompanied by an increase in both the intestinal levels of the calcium binding protein as well as of strontium with has also been observed in the Here the administration of a high strontium dose inhibited both the of and intestinal calcium However, whereas with calcium absorption, administration of had effect. These data indicate that strontium, by a yet may the of from which in may be responsible for the development of so-called strontium-induced 42, 43 In this the in vivo observation that and their activity in the presence of high strontium concentrations is also of particular one can that high doses of strontium may indirectly affect bone metabolism by the intestinal absorption of calcium, the concentration of the and the of to interesting finding in the increased osteogenesis noted in the presence of low strontium doses was that it was not accompanied by in levels of by in intact levels. in experimental studies in rats with normal renal function, the administration of low strontium doses has been associated with a in the serum calcium levels which was observed during particular of rapid growth of the This may have resulted from a diminished intestinal absorption of calcium due to of the element with strontium. The in the calcium that was observed at that however, may have resulted from a strontium-induced calcium from bone at the of in contrast to these in our experimental study using chronic renal failure rats, differences in serum calcium levels were observed between control and However, the calcium was increased in rats that had strontium. this was not due to increased it was suggested that this observation might have been the result of a incorporation of calcium in bone to the presence of strontium, a of calcium by strontium in the hydroxyapatite or a direct effect of strontium on the of With to the the agonistic effect of strontium with the calcium-sensing at the of the should not be noted that bone strontium levels in dialysis patients with osteomalacia were increased as compared with all other of renal such as mild adynamic bone, and the found bone strontium levels to correlate with bone aluminum levels within this was a of the bone strontium levels and bone calcium levels noted in the osteomalacic patients as compared with that noted for the other of renal At it is not whether in the osteomalacic patients strontium has either a or role in the development of this disease is it known the increased bone strontium concentrations are an of the osteomalacic is still as to what extent strontium in dialysis patients and whether accumulation is due to the impaired renal function, the dialysis the diet, or a combination of It is worth that as as et and on et suggested a potential role for strontium in the development of renal Interestingly, in the of this accumulation of strontium levels has been associated with the development of bone Recently, an study in demonstrated a significantly of the of in in a with a high strontium content and where was mainly on as compared with that in in a low strontium et al. found that the particular form of by strontium from those induced by calcium or in that supplements not the on this was to the element's ability to inhibit the in vivo of the active 42, 43 We have a study in the of which serum strontium levels were found to be with renal function. in patients treated by hemodialysis, serum strontium levels greatly from center to center and to (range ± μg/l up to 466 ± 90 In the latter revealed that increased serum strontium levels μg/l) could for be by the of dialysis whereas the diet, and dialysis appeared to play only a In an experimental study using the oral strontium loading resulted in histologic bone lesions characterized by an increased amount of osteoid in the presence of a decreased mineralization indicating the presence of osteomalacia and toward a role of the element in the development of this particular type of renal A direct effect of strontium on bone mineralization may be suggested from the element's localization in bone. Indeed, strontium could be localized in calcified bone, mainly in bone close to the a site of bone mineralization. findings were by osteoblast from rat are used to study the mechanism by which strontium interferes with the bone mineralization either directly or indirectly via its interaction with bone matrix such as bone sialoprotein, and The that in the development of the osteomalacic lesions in dialysis patients strontium via an indirect pathway can not be a direct effect on the element's activity has also been ascribed to interferences with gastrointestinal absorption, and in the concentration of the Here the of human renal cell as well as renal cell able to are of particular interest to demonstrate an effect of the element on is a of a from the of of our and experimental studies were performed in the of an